MIAMI, FL (February 5, 2024) – Lavior Pharma Inc., an International advanced diabetic wound and skincare Company headquartered in Miami, Florida, announced the appointment of Alton Johnson, DPM to the Company’s Scientific Executive Advisory Board. Dr. Johnson is a Clinical Assistant Professor of Orthopedic Surgery specializing in Foot and Ankle disorders with an emphasis on Podiatric Surgery at the University of Michigan Medical School. Dr. Johnson completed his medical education at Kent State University College of Podiatric Medicine and completed post-graduate Podiatric Medicine and Surgery training at HCA Florida Aventura Hospital in Miami, FL. Dr. Johnson brings a wealth of knowledge and expertise in podiatric surgery, emphasizing wound healing and prevention. He is board certified in Podiatric Medicine by the American Board of Podiatric Medicine. In addition, Dr. Johnson is a Board-Certified Wound Care Specialist Physician by the American Board of Wound Management. Dr. Johnson serves as a Board Member of Kent State University College of Podiatric Medicine and Chairman of the Board of Directors for the American Society of Podiatric Surgeons. He is an internationally recognized expert, speaker, and has authored dozens of peer-reviewed articles in wound management.
Dr. Johnson shares, “I am honored to be invited to join Lavior’s Scientific Executive Advisory Board. Lavior is quickly becoming the recognized leader in wound care management. Their mission of not just managing wounds but healing them to prevent amputation aligns with my goals to identify safe, effective, affordable, and accessible treatments to reduce and prevent diabetic-related complications, especially in marginalized communities. I look forward to joining their scientific team of experts in helping patients across the globe.”
“We are excited to have Dr. Johnson join our Scientific Executive Leadership team. We welcome his unwavering commitment, passion, and expertise to help support and improve patients lives. He will assist us in our ongoing research and regulatory efforts to bring the latest technology and solutions to market and to address the limitations with conventional therapies. His addition to the Advisory Board will further support Lavior’s role as the worldwide wound care leader,” says Gilad Savion, the CEO and President of Lavior.
About Lavior Pharma Inc.
LAVIOR is the only company exclusively dedicated to the therapeutic diabetes skin care market. The LAVIOR skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations, and cracked skin. LAVIOR’s line of products is based on the proven efficacy of the Inula AGS RIED botanical species. They are developed using the highest quality, pharmaceutical grade ingredients; manufactured and tested to deliver safe, effective, and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.
For more information on Lavior Pharma and its products, please visit www.lavior.com
For Media or other Inquiries, please contact:
Phone: (+1) 9178373355